oral semaglutide trials Efficacy, safety and cardiovascular outcomes of once‐daily in patients with type 2 diabetes: The PIONEER programme - Thethi - 2020 - Diabetes, Obesity and Metabolism Efficacy, safety and cardiovascular outcomes

Among people with pre-existing SUDs, initiation of GLP-1 receptor agonists was associated with reduced risk of SUD related emergency department visits (0.69 (0.61 to 0.78), NRD 8.92 (11.59 to 6.25)), SUD related hospital admissions (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and drug overdose (0.61 (0.42 to 0.88), NRD 1.49 (2.43 to 0.55)) and suicidal ideation or attempt (0.75 (0.67 to 0.83), NRD 9.95 (13.14 to 6.77))

This is nearing the levels obtained by

Best semaglutide shots for weight loss in Boca Raton, FL

Why Researchers Are Interested in Retatrutide

Trial registration Clinicaltrials.gov, NCT04777396 and NCT04777409